Evidence map›Paper›PMID 41125968›Full record

ArticleMetabolomics : Official journal of the Metabolomic Society2025

Investigating stage-specific metabolic alterations in colorectal cancer through urine metabolomics.

Feng Qi, Yulin Sun, Jiaqi Liu, Xiaoyan Liu, Haidan Sun, Zhengguang Guo, Binbin Zhang, Jiameng Sun, Aiwei Wang, Hezhen Lu and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Feng Qi *Proteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Yulin Sun *State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiaqi Liu *Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.
Xiaoyan LiuProteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Haidan SunProteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Zhengguang GuoProteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Binbin ZhangDepartment of Pharmacy, No.79 Army Group Hospital of People's Liberation Army Ground Force, Liaoyang, 111000, China.
Jiameng SunProteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Aiwei WangProteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China.
Hezhen LuDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.
Fei XueDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.
Tingmiao LiDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China.
Xin QiDepartment of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun, China. qxin@jlu.edu.cn.
Xiaohang ZhaoState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhaoxh@cicams.ac.cn.
Wei SunProteomics Research Center, Core Facility of Instruments, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing, China. sunwei@ibms.pumc.edu.cn.

Funding

Beijing Medical Research No.2018-7CAMS Innovation Fund for Medical Sciences 2021-I2M-1-016,2022-I2M-1-020 and 2021-I2M-1-066National Natural Science Foundation of China No.82170524,31901039 and 82073327
6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) ranks as the third most prevalent malignancy globally, presenting a formidable early diagnostic challenge. An effective biomarker with high sensitivity and specificity can help diagnose CRC and improve the chances of successful treatment.

methods100 healthy controls and 95 CRC patients (25 Stage 0/I, 30 stage II and 40 stage III based on Clinical stages) were recruited. Subsequently, 195 urine samples were subjected to UPLC-MS analysis. Comparative analysis was employed to elucidate noteworthy metabolic variances, and pathway analysis was conducted to unveil perturbed metabolic functions. Ultimately, metabolic panels for CRC diagnosis were constructed.

resultA total of 82 metabolites exhibited statistical significance between CRC patients and healthy controls. Moreover, pathway analysis revealed that they were associated with Steroid hormone biosynthesis, Nitrogen metabolism, and D-Glutamine and D-glutamate metabolism. A composite panel consisting of Retinol, L-β-aspartyl-L-glycine, and 21-Deoxycortisol showed AUCs of 0.933/0.93 in the discovery/validation group. The panel also showed commendable efficacy across different CRC stages when these stages were compared with the healthy group,with an AUC of 0.918 for stages 0/I, 0.862 for stage II, and 0.845 for stage III.

conclusionsUrine metabolome could distinguish CRC from healthy controls and reflect the changes in different stages of CRC. Potential biomarkers might be developed by targeted metabolomic analysis.

Indexed as

Biomarkers, TumorColorectal NeoplasmsMetabolomicsAdultAgedCase-Control StudiesFemaleHumansMaleMass SpectrometryMetabolomeMiddle AgedNeoplasm StagingBiomarkers, TumorColorectal cancerDiagnostic biomarkerUrine non-targeted metabolomics

Identifiers

PMID41125968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.